

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 1 022 337 A2**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
**26.07.2000 Bulletin 2000/30**

(51) Int. Cl.<sup>7</sup>: **C12N 15/24**, C12N 15/70,  
C12N 15/72

(21) Application number: **00100129.6**

(22) Date of filing: **07.01.2000**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

(30) Priority: **20.01.1999 EP 99100967**

(71) Applicant: **BAYER AG**  
**51368 Leverkusen (DE)**

(72) Inventors:  
• **Apeler, Heiner, Dr.**  
**42111 Wuppertal (DE)**  
• **Wehlmann, Hermann, Dr.**  
**42349 Wuppertal (DE)**

(54) **Plasmids, their construction and their use in the manufacture of interleukin-4 and interleukin-4 muteins**

(57) The present invention relates to the construction and use of expression plasmids in the manufacture of recombinant interleukin-4 (IL-4) and interleukin-4 muteins.

**EP 1 022 337 A2**

## Description

### Field of the Invention

5 [0001] The present invention relates to the construction and use of expression plasmids in the manufacture of recombinant interleukin-4 (IL-4) and interleukin-4 muteins.

### Background of the Invention

10 [0002] Mature human interleukin-4 (IL-4) is composed of 129 amino acids with 50% homology to mouse IL-4. IL-4 is the only cytokine known to direct the differentiation of T helper cells to a T<sub>H2</sub> phenotype (Mosmann and Sad, Immunol. Today 17, 138 - 146, 1996). IL-4 signals on lymphocytes and other cells through a heterodimeric complex of two cytokine receptors, the IL-4R $\alpha$  and the common  $\gamma$ -chain ( $\gamma$ c). Antagonistic IL-4 mutants have been described (Kruse et al., EMBO J. 11, 3237 - 3244, 1992). Three amino acids close to the C-terminus (R121, Y124 and S125) are important  
15 for binding to the  $\gamma$ c-chain. The introduction of Asp (D) into these positions blocks receptor dimerization and transmembrane signaling.

[0003] The interleukin-4 double mutein (IL-4 DM) is an IL-4 variant with 2 amino acid changes in position 121 and 124 termed IL-4 R121D Y124D. IL-4 DM is able to block both IL-4 and IL-13 activities. In contrast to all single site mutants no residual agonistic activity has ever been found for this mutein. It is believed that these antagonistic properties of IL-4 DM are useful for the treatment of diseases which involve T<sub>H2</sub> development and/or IgE production (Ryan, J. Allergy Clin. Immunol. 99, 1 - 5, 1997).  
20

[0004] As described in various publications, procaryotic organisms can be used to produce recombinant IL-4 and IL-4 muteins. Unfortunately, the described systems have a number of drawbacks (low expression level, low stability of the expression vector) which make large scale production of IL-4 and IL-4 muteins impossible or economically unfeasible.  
25

[0005] The main criteria for an efficient and safe expression system are:

- high product yield
- regulatable stable expression
- 30 • stability of the expression vector

[0006] Several features of an expression plasmid are important for the criteria listed above (Hannig et al., TIBTECH. 16, 54 - 60, 1998). These are:

- 35 • Promoter
- Ribosomal binding site (rbs)
- Codon usage of the corresponding gene
- Transcriptional terminator
- Resistance gene
- 40 • Regulation of expression
- Origin of replication (ori)

### Summary of the Invention

45 [0007] Expression plasmids for IL-4 and IL-4 muteins with modifications in all of the relevant elements for an efficient and safe expression system were generated. The quality and suitability of the corresponding expression system was ranked mainly according to the following criteria:

- Yield of IL-4 and IL-4 muteins
- 50 • Plasmid stability
- Maintenance of induction capability

[0008] The object of the present invention is, therefore, to make available a process for the construction and use of expression plasmids in the large scale manufacture of recombinant interleukin-4 (IL-4) and interleukin-4 muteins. In addition the newly developed host/vector system should be well suited for the expression of other proteins (cytokines, growth factors, soluble receptors, antibodies etc.).  
55

[0009] Surprisingly, it has been found that bacteria transformed with plasmids according to the present invention give expression rates, plasmid and expression stability values many times higher than those observed after transform-

ing the identical hosts with plasmids known in the art. Therefore, the plasmids of this invention are far more useful for the preparation of recombinant interleukin-4 and interleukin-4 muteins than all plasmids previously known.

**[0010]** The newly developed vector system contains the following elements:

#### 5 **T5 promoter**

**[0011]** The E. coli phage T5 promoter together with two lac operator sequences is derived from the pQE30 plasmid (Qiagen) belonging to the pDS family of plasmids (Bujard et al., Methods Enzymol. 155, 416 - 433, 1987 and Stüber et al., Immunological Methods, I. Lefkovits and B. Pernis, eds., Academic Press, Inc., Vol. IV, 121 - 152, 1990).

10

#### **T7 g10 ribosomal binding site**

**[0012]** The ribosomal binding site (rbs) is derived from the region upstream from gene 10 of the phage T7 (T7 g 10 leader). Gene 10 of phage T7 codes for the coat protein, which is the major protein expressed after T7 infection. The T7 g 10 rbs was obtained from the vector pET-9a (Studier et al., Methods Enzymol. 185, 60 - 89, 1990). The T7 g10 leader spans a region of about 100 bp (Olins et al., Gene 227 - 235, 1988). In the final expression construct the region upstream of the XbaI site is deleted. The T7 g10 leader sequence now spans 42 bp and harbours one base exchange from G to A in position 3638 of the preferred plasmid.

15

#### 20 **Codon usage of the natural IL-4 sequence**

**[0013]** As an effective measure of synonymous codon usage bias, the codon adaptation index (CAI) can be useful for predicting the level of expression of a given gene (Sharp et al., Nucleic Acids Res. 15, 1281 - 1295, 1987 and Apeler et al., Eur. J. Biochem. 247, 890 - 895, 1997). The CAI is calculated as the geometric mean of relative synonymous codon usage (RSCU) values corresponding to each of the codons used in a gene, divided by the maximum possible CAI for a gene of the same amino acid composition. RSCU values for each codon are calculated from very highly expressed genes of a particular organism, e.g. E. coli, and represent the observed frequency of a codon divided by the frequency expected under the assumption of equal usage of the synonymous codons for an amino acid. Highly expressed genes, e.g. genes encoding ribosomal proteins, have generally high CAI values  $\geq 0.46$ . Poorly expressed genes like lacI and trpR in E. coli have low CAI values  $\leq 0.3$ .

25

30

**[0014]** The calculated E. coli CAI value for the natural IL-4 sequence is 0.733. This means that the natural gene should be well-suited for high level expression in E. coli. Nevertheless a synthetic gene with optimal E. coli codon usage (CAI value = 1) has the potential to further increase the expression level. Therefore synthetic IL-4 and IL-4 mutein genes were designed and cloned.

35

#### **Transcriptional terminator**

**[0015]** A T7 DNA fragment containing the transcription terminator T $\phi$  is derived from the vector pET-9a (Studier et al., Methods Enzymol. 185, 60 - 89, 1990). Transcriptional terminators determine the points where the mRNA-RNA polymerase-DNA complex dissociates, thereby ending transcription. The presence of a transcriptional terminator at the end of a highly expressed gene has several advantages: they minimize sequestering of RNA polymerase that might be engaged in unnecessary transcription, they restrict the mRNA length to the minimal, thus limiting energy expense, as strong transcription may interfere with the origin of replication, a transcriptional terminator increases plasmid stability due to copy number maintenance (Balbas and Bolivar, Methods Enzymol. 185, 14 -37, 1990).

40

45

#### **Resistance gene**

**[0016]** The kan resistance gene is derived from the vector pET-9a (Studier et al., Methods Enzymol. 185, 60 -89, 1990). Originally, this is the kan gene of Tn903 from the vector pUC4KISS (Barany, Gene 37, 111 - 123, 1985). In the preferred plasmid the kan gene and the IL-4 and IL-4 mutein gene have opposite orientations, so there should not be an increase in kan gene product after induction due to read-through transcription from the T5 promoter. Kanamycin was chosen as selective marker because it is the preferred antibiotic for GMP-purposes. In addition, kan gene based vectors are more stable than ampicillin resistant (bla) plasmids. Ampicillin selection tends to be lost in cultures as the drug is degraded by the secreted  $\beta$ -lactamase enzyme. The mode of bacterial resistance to kanamycin relies upon an aminoglycoside phosphotransferase that inactivates the antibiotic.

50

55

## Regulation of expression

[0017] Controlled gene expression is absolutely necessary for the set-up of a stable plasmid system, particularly if the protein of interest is deleterious to the host cell. The preferred plasmid uses a lac-based inducible system consisting of a lac repressor gene (*lacI*) and two synthetic lac operator sequences fused downstream to the *E. coli* phage T5 promoter. The *lacI*<sup>q</sup> promoter and the *lad* structural gene were isolated from the vector pTrc99A (Amann et al., Gene 69, 301 - 315, 1988). *I*<sup>q</sup> is a promoter mutation which leads to overproduction of the *lad* repressor. The wild-type lac repressor is a tetrameric molecule comprising four identical subunits of 360 amino acids each. The lac repressor tetramer is a dimer of two functional dimers. The four subunits are held together by a four-helix bundle formed from residues 340 - 360. Due to the isolation of the *lacI* gene from the vector pTrc99A by a *NarI* cut the residues beyond amino acid 331 are deleted and 10 amino acids not normally encoded in the *lacI* gene are added. It is known that mutations or deletions that occur in the C-terminal part of *lad*, beyond amino acid 329, result in functional dimers that appear phenotypically similar to the wild-type repressor (Pace et al., TIBS 22, 334 - 339, 1997).

## Origin of replication (*ori*)

[0018] The origin of replication (*ori*) of the preferred plasmid is derived from the vector pET-9a, the *ori* of which originates from pBR322. The preferred plasmid therefore carries the pMB1 (*ColE1*) replicon. Plasmids with this replicon are multicopy plasmids that replicate in a 'relaxed' fashion. A minimum of 15 - 20 copies of plasmid are maintained in each bacterial cell under normal growth conditions. The actual number for the preferred plasmid is within this range. Replication of the *ColE1*-type *ori* is initiated by a 555-nucleotide RNA transcript, RNA II, which forms a persistent hybrid with its template DNA near the *ori*. The RNA II-DNA hybrid is then cleaved by RNase H at the *ori* to yield a free 3'OH that serves as a primer for DNA polymerase I. This priming of DNA synthesis is negatively regulated by RNA I, a 108-nucleotide RNA molecule complementary to the 5' end of RNA II. Interaction of the antisense RNA I with RNA II causes a conformational change in RNA II that inhibits binding of RNA II to the template DNA and consequently prevents the initiation of plasmid DNA synthesis. The binding between RNAs I and II is enhanced by a small protein of 63 amino acids (the Rop protein, Repressor of primer), which is encoded by a gene located 400 nucleotides downstream from the origin of replication (Sambrook et al., Molecular Cloning, Cold Spring Harbor, 1989). Deletion of the *rop* gene leads to an increase in copy number and due to a gene dosage effect to enhanced expression levels of the plasmid encoded heterologous gene. This observation was also made for the IL-4 expression vectors tested. But it turned out that *rop*<sup>-</sup>-plasmids are unstable and lost very rapidly during fermentation under non-selective conditions. Therefore the replicon of the preferred plasmid contains the *rop* gene to ensure high plasmid stability. The preferred plasmid lacks the *mob* gene that is required for mobilization and is therefore incapable of directing its own conjugal transfer from one bacterium to another.

[0019] In the preferred plasmid all elements not necessary for plasmid replication, resistance and regulatable expression were deleted.

[0020] To fall within the scope of the present invention, not all of the above features have to be incorporated in the construction of the preferred expression plasmid. For example, a natural interleukin-4 or interleukin-4 mutein gene can be used instead of a synthetic one with optimized *E. coli* codon usage. The preferred transcription terminator is T $\phi$ , but other terminators like *rrnB* T2 or *aspA* can also be used. Likewise, it is possible to take the elements for the construction of the preferred plasmid from other than the herein described commercially available vectors.

[0021] The methods employed in the course of the establishment of the expression system are given below.

## MATERIALS AND METHODS

### Enzymes

[0022] Restriction endonucleases, calf intestinal alkaline phosphatase, T4 polynucleotide kinase and T4 DNA ligase were purchased from Boehringer Mannheim and GIBCO-BRL and used as recommended by the supplier.

### Recombinant DNA methods

[0023] Standard cloning procedures have been described in Sambrook et al. (Molecular Cloning, Cold Spring Harbor, 1989). Transformations were performed according to M. Scott (Seed and Aruffo, Proc. Natl. Acad. Sci. USA 84, 3365 - 3369, 1987). As hosts for transformations the *E. coli* strains DH5 $\alpha$  (GIBCO BRL) and W3110 (ATCC 27325) were primarily used. The genotype of W3110 is K12, F<sup>-</sup>, [N(*rrnD*-*rrnE*)] $\lambda$ <sup>-</sup>.

[0024] Large scale isolations of plasmid DNA were carried out with Qiagen-tips (Qiagen). Extraction of DNA fragments from agarose gels was performed using Jetsorb (Genomed) as recommended by the supplier.

[0025] Oligonucleotides for site directed mutagenesis, PCR reactions and sequencing were obtained from MWG Biotech, Pharmacia Biotech or GIBCO BRL.

[0026] The mutagenesis experiments were carried out by the method of Deng and Nickoloff (Deng and Nickoloff, Anal. Biochem. 200, 81 - 88, 1992) using the 'Unique Site Elimination Mutagenesis' system from Pharmacia Biotech.

The primer used for the recreation of the T7 g10 rbs has the following sequence:

5'TCAATTGTGAGCGGATAACAATTTTCACACATCTAGAAATAATTTTGTTT  
AACTTTAAGAA3' (Seq.1).

[0027] All constructs and DNA sequences were confirmed using Dye Terminator Cycle Sequencing with AmpliTaq DNA Polymerase, FS on an ABI 373A sequencer (Applied Biosystems).

[0028] The invention is explained in more detail by the following examples, figures and sequences information:

FIG.1 to FIG.4: Construction of the preferred expression plasmid. (Abbreviations: IL-4 TM, IL-4 triple mutein; IL-4 DM, IL-4 double mutein).

FIG. 5: Plasmid stability of the IL-4 mutein expression vectors pRO21.1.O and pRO2.1.O. The vector pRO2.1.O remains fully stable over 78 generations without antibiotic selection. In contrast the expression vector pRO21.1.O, which is based on the commercially available plasmid pET-30a (Novagen), is lost very rapidly. Only 16% of the colonies contain the plasmid after 78 generations without kanamycin selection.

FIG. 6: Maintenance of induction and expression capability of the preferred IL-4 and IL-4 mutein expression vector.

## EXAMPLES

### Example 1

#### Plasmid stability test

[0029] The plasmid stability tests were always started with a culture frozen in liquid nitrogen. The OD<sub>600</sub> of the thawed culture was determined, the culture diluted up to 10<sup>-4</sup> in PBS buffer and plated on LB agar plates without antibiotic.

[0030] 1 ml of the thawed culture was inoculated into 100 ml of peptone medium (30 g Soya peptone, 20 g Yeast extract, 5 g KH<sub>2</sub>PO<sub>4</sub>, 20 g Glycerol, 1 g MgSO<sub>4</sub> x 7H<sub>2</sub>O per liter, pH 7,0) and incubated at 37°C with 280 rpm for 24 hours.

[0031] The OD<sub>600</sub> of the grown culture was determined, the culture diluted up to 10<sup>-6</sup> in PBS buffer and plated on LB agar plates without antibiotic to get well separated colonies.

[0032] 100 µl from the grown culture were inoculated into 100 ml peptone medium and incubated at 37°C with 280 rpm for 24 hours. This procedure was repeated eight times.

[0033] 100 well separated colonies from the LB plates were gridded onto LB plates with kanamycin (25 µg/ml) and LB plates without kanamycin and incubated at 37°C overnight. The percentage of resistant colonies was determined on every day.

[0034] The number of generations per day were calculated according to the following formula:  
 $\log [\text{OD}_{600 \text{ END}} / \text{OD}_{600 \text{ BEG}}] / \log 2$ .

[0035] For the expression studies 1 ml of a grown culture was diluted 100 fold into LB medium and handled as described (see Example 2).

### Example 2

#### Expression

[0036] For small scale expression of interleukin-4 and interleukin-4 muteins cells were grown in LB medium (10 g

## EP 1 022 337 A2

Bacto tryptone, 5 g Yeast extract, 10 g NaCl per liter, pH 7,5) until OD600 reached 0.8 - 1.0. Expression was induced by addition of IPTG to a final concentration of 0,5 mM and incubation continued for 5 hours. Cells were harvested by centrifugation.

**[0037]** For SDS-PAGE analysis cell pellets were resuspended in SDS-PAGE loading buffer to a concentration of 1 OD600 unit/100  $\mu$ l.

5

10

15

20

25

30

35

40

45

50

55

## SEQUENCE LISTING

5 <110> Bayer AG  
 <120> PLASMIDS, THEIR CONSTRUCTION AND THEIR USE IN THE  
 MANUFACTURE OF INTERLEUKIN-4 AND INTERLEUKIN-4 MUTEINS  
 <130> Plasmids for IL-4 muteins  
 10 <140>  
 <141>  
 <160> 2  
 <170> PatentIn Ver. 2.0  
 15 <210> 1  
 <211> 60  
 <212> DNA  
 <213> Unknown  
 20 <220>  
 <223> Description of Unknown Organism: primer  
 <400> 1  
 tcaattgtga gcggataaca atttcacaca tctagaaata attttgttta actttaagaa 60  
 25 <210> 2  
 <211> 4202  
 <212> DNA  
 <213> Unknown  
 30 <220>  
 <223> Description of Unknown Organism: Human  
 <400> 2  
 ttagaaaaac tcatcgagca tcaaatgaaa ctgcaattta ttcatatcag gattatcaat 60  
 accatatattt tgaaaaagcc gtttctgtaa tgaaggagaa aactcaccga ggcagttcca 120  
 35 taggatggca agatcctggt atcgggtctgc gattccgact cgtccaacat caatacaacc 180  
 tattaatttc cctcgtcaa aaataagggt atcaagttag aaatcaccat gagtgacgac 240  
 tgaatccggt gagaatggca aaagcttatg catttctttc cagacttggt caacaggcca 300  
 gccattacgc tcgtcatcaa aatcactcgc atcaacccaaa ccgttattca ttcgtgattg 360  
 cgctgagcgc agacgaaata cgcgatcgcgt gttaaaagga caattacaaa caggaatcga 420  
 atgcaaccgg cgcaggaaca ctgccagcgc atcaacaata ttttcacctg aatcaggata 480  
 40 ttcttctaata acctggaatg ctgttttccc ggggatcgca gtggtgagta accatgcac 540  
 atcaggagta cggataaaat gcttgatggt cggaagaggc ataaattccg tcagccagtt 600  
 tagtctgacc atctcatctg taacatcatt ggcaacgcta cctttgccat gtttcagaaa 660  
 caactctggc gcatcgggct tccatacaaa tcgatagatt gtcgcacctg attgcccgac 720  
 attatcgcca gccattttat acccatataa atcagcatcc atgttggaat ttaatcgcg 780  
 cctcgagcaa gacgtttccc gttgaatatg gctcataaca ccccttgat tactgtttat 840  
 45 gtaagcagac agttttattg ttcatgacca aaatccctta acgtgagttt tctgtccact 900  
 gagcgtcaga ccccgtagaa aagatcaaag gatcttcttg agatcctttt tttctgcgcg 960  
 taatctgctg cttgcaaaca aaaaaaccac cgtaccagc ggtggttgt ttgccggatc 1020  
 aagagctacc aactcttttt ccgaaggtaa ctggcttcag cagagcgagc ataccaaata 1080  
 ctgtccttct agttagccg tagttaggcc accacttcaa gaactctgta gcaccgccta 1140  
 catacctcgc tctgctaata ctgttaccag tggctgctgc cagtggcgat aagtcgtgtc 1200  
 50 ttaccggggt ggactcaaga cgatagttac cggataaggc gcagcggtcg ggctgaacgg 1260  
 ggggttcgtg cacacagccc agcttgagc gaacgacct caccgaactg agataacctac 1320  
 agcgtgagct atgagaaagc gccacgcttc ccgaaggag aaaggcggac aggtatccgg 1380  
 taagcggcag ggtcggaaca ggagagcgca cgaggagct tccaggggga aacgcctggt 1440  
 55

atctttatag tcctgtcggg ttctgccacc tctgacttga gcgtcgattt ttgtgatgct 1500  
 cgtcaggggg ggggagccta tggaaaaacg ccagcaacgc ggccttttta cggttcctgg 1560  
 5 ccttttcttg gctttttgct cacatgttct ttcttgcgtt atccccgat tctgtggata 1620  
 accgtattac cgcttttgag tgagctgata ccgctcgccg cagccgaacg accgagcgca 1680  
 gcgagtcagt gaggcaggaa gcggaagagc gcctgatgcg gtattttctc cttacgcata 1740  
 tgtgcggtat ttacaccgc aatggtgcac tctcagtaca atctgctctg atgccgcata 1800  
 gttaagccag tatacactcc gctatcgcta cgtgactggg tcatggctgc gccccgacac 1860  
 ccgccaacac ccgctgacgc gccctgacgg gcttgtctgc tcccgcatc cgcttacaga 1920  
 10 caagctgtga ccgtctccgg gagctgcatg tgctcagagg ttccaccgtc atcacgaaa 1980  
 cgcgcgaggg agctgcggta aagctcatca gcgtggctcg gaagcgattc acagatgtct 2040  
 gcctgttcat ccgctgccag ctctgtgagt ttctccagaa gcgttaatgt ctggcttctg 2100  
 ataaagcggg ccattgttaag ggcggttttt tctgttttg tcaactgatgc ctccgtgtaa 2160  
 gggggatttc tgttcatggg ggtaatgata ccgatgaaac gagagaggat gctcacgata 2220  
 cgggttactg atgatgaaca tgcccgttta ctggaacgtt gtgagggtaa acaactggcg 2280  
 15 gtatggatgc ggcgggacca gagaaaaatc actcagggtc aatgccagcg ctcatgagcc 2340  
 cgaagtggcg agcccgatct tccccatcgg tgatgtcggc gatataggcg ccagcaaccg 2400  
 cacctgtggc gccggtgatg ccggccacga tgcgtccggc gtagaggatc gagatccatt 2460  
 tacgttgaca ccattcgaatg gtgcaaaaac ttctcgcgta tggcatgata gcgcccggaa 2520  
 gagagtcaat tcaggggtgt gaatgtgaaa ccagtaacgt tatacgtatg cgcagagtat 2580  
 gccggtgtct cttatcagac cgtttccgcg gtggtgaacc aggccagcca cgtttctgcg 2640  
 20 aaaacgcggg aaaaagtggg agcggcgatg gcggagctga attacattcc caaccgcgtg 2700  
 gcacaacaac tggcggggcaa acagtctgtg ctgattggcg ttgccacctc cagtctggcc 2760  
 ctgcacgcgc cgtcgcaaat tctcgcgcg attaaatctc gcgccgatca actgggtgcc 2820  
 agcgtgtgtg tgcgatggt agaacgaag gcgctgaag cctgtaaaag ggcggtgcac 2880  
 aatcttctcg cgcaacgcgt cagtgggtg atcattaact atccgctgga tgaccaggat 2940  
 25 gccattgctg tggaaagctg ctgactaat gtccggcggt tatttcttga tgtctctgac 3000  
 cagacaccca tcaacagtat tattttctcc catgaagacg gtacgcgact gggcgtggag 3060  
 catctggtcg cattgggtca ccagcaaat gcgtgttag cgggccatt aagttctgtc 3120  
 tcggcgctgc tgcgtctggc tggctggcat aaatatctca ctcgcaatca aattcagccg 3180  
 atagcggaac gggaaggcga ctggagtgcc atgtccggtt ttcaacaaac catgcaaatg 3240  
 ctgaatgagg gcatcgttcc cactgcgatg ctggttgcca acgatcagat ggcgctgggc 3300  
 30 gcaatgcgcg ccattaccga gtccgggctg cgcggttggt cggatatctc ggtagtggga 3360  
 tacgacgata ccgaagacag ctcatgttat atcccgccg taaccaccat caaacaggat 3420  
 ttctgcctgc tggggcaaac cagcgtggac cgcttgctgc aactctctca gggccaggcg 3480  
 gtgaagggca atcagctgtt gccctctca ctggtgaaaa gaaaaaccac cctggctcga 3540  
 gaaatcataa aaaatttatt tgctttgtga gcggataaca attataatag attcaattgt 3600  
 gagcggataa caatttcaca catctagaaa taattttatt taactttaag aaggagatat 3660  
 35 acatatgcac aaatgcgata tcaccctgca ggaaatcatc aaaaccctga attctctgac 3720  
 cgaacgaaa accctgtgca ccgaactgac cgttaccgac atcttctctg cttcgaaaaa 3780  
 caccaccgaa aaagaaacct tctgccgtgc tctaccgtt ctgcgtcagt tctactctca 3840  
 ccacgaaaaa gacaccgtt gcctgggtgc taccgctcag cagttccacc gtcacaaaca 3900  
 gctgatccgt ttctgaaac gtctggaccg taacctgtgg ggtctggctg gtctgaacag 3960  
 ctgcccggtt aaagaagcta accagtctac cctggaaaaac ttctggaac gtctgaaaac 4020  
 40 catcatggac gaaaaagact ctaaatgtct ttcttaataa ggatccggct gctaacaaag 4080  
 cccgaaagga agctgagttg gctgctgcca ccgctgagca ataactagca taacccttg 4140  
 gggcctctaa acgggtcttg aggggttttt tgctgaaagg aggaactata tccggataat 4200  
 tc 4202

## Claims

1. An operon for the manufacture of IL-4 and IL-4 muteins in a strain of *Escherichia coli*, comprising in 5' to 3' order the following operatively linked elements: a regulatable promoter consisting of the *E. coli* phage T5 promoter and two lac operator sequences, a ribosome binding site from the *E. coli* phage T7 g10, a translational start codon, a structural gene for IL-4 or an IL-4 mutein and downstream of that structural gene one transcription terminator.
2. *E. coli* / pRO2.1.O
3. *Escherichia coli* transformed with one or more of the plasmids of claims 1 or 2.



4. Use of the plasmids according to claims 1 or 2 in a method of preparation of IL-4 and IL-4 muteins.

5

10

15

20

25

30


35

40

45

50

55



**Fig. 1**




Fig. 2




Fig. 3




Fig. 4

Fig. 5





Fig. 6



SDS-PAGE (15 %) analysis of total extracts from *E. coli*/pRO2.1.O grown for different numbers of generations without antibiotic selection after 5 hours of induction with 0,5 mM IPTG. 10  $\mu$ l of the resuspended cell pellets was applied to each slot. The gel was run under reducing conditions and stained with Coomassie brilliant blue.

- Lane 1: Molecular weight marker (Low Range, Life Technologies)
- Lane 2: IL-4 mutein (5  $\mu$ g)
- Lane 3: *E. coli*/pRO2.1.O (8 generations) before induction
- Lane 4: *E. coli*/pRO2.1.O (8 generations) after induction
- Lane 5: *E. coli*/pRO2.1.O (18 generations) after induction
- Lane 6: *E. coli*/pRO2.1.O (28 generations) after induction
- Lane 7: *E. coli*/pRO2.1.O (38 generations) after induction
- Lane 8: *E. coli*/pRO2.1.O (48 generations) after induction
- Lane 9: *E. coli*/pRO2.1.O (58 generations) after induction
- Lane 10: *E. coli*/pRO2.1.O (68 generations) after induction
- Lane 11: *E. coli*/pRO2.1.O (78 generations) before induction
- Lane 12: *E. coli*/pRO2.1.O (78 generations) after induction
- Lane 13: Molecular weight marker (Low Range, Life Technologies)
- Lane 14: Molecular weight marker (High Range, Life Technologies)

**PUB-NO:** EP001022337A2  
**DOCUMENT-IDENTIFIER:** EP 1022337 A2  
**TITLE:** Plasmids, their construction and their use in the manufacture of interleukin-4 and interleukin-4 muteins  
**PUBN-DATE:** July 26, 2000

**INVENTOR-INFORMATION:**

<b>NAME</b>	<b>COUNTRY</b>
APELER, HEINER DR	DE
WEHLMANN, HERMANN DR	DE

**ASSIGNEE-INFORMATION:**



**NAME**                      **COUNTRY**

BAYER AG      DE

**APPL-NO:**      EP00100129

**APPL-DATE:**   January 7, 2000

**PRIORITY-DATA:**   EP00100129A  
                              (January 7,  
                              2000) ,  
                              EP99100967A  
                              (January 20, 1999)

**INT-CL**                      C12N015/24 ,  
**(IPC) :**                      C12N015/70 ,  
                                  C12N015/72

**EUR-CL (EPC) :**   C07K014/54

**ABSTRACT :**

CHG DATE=20000901 STATUS=O> The  
present invention relates to the  
construction and use of expression

plasmids in the manufacture of  
recombinant interleukin-4 (IL-4)  
and interleukin-4 muteins.